Vergleich mehrerer Laborproben (Symbolbild).
Mittwoch, 02.10.2024 08:00 von

Boston Scientific Announces Conference Call Discussing Third Quarter 2024 Results

Vergleich mehrerer Laborproben (Symbolbild). pixabay.com

PR Newswire

-Company to also host virtual webcast with a cardiology business update-

MARLBOROUGH, Mass., Oct. 2, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the third quarter ended September 30, 2024, on Wednesday, October 23, 2024, at 8:00 a.m. ET. The call will be hosted by Mike Mahoney, chairman and chief executive officer, and Dan Brennan, executive vice president and chief financial officer. The company will issue a news release announcing financial results for the third quarter on October 23 prior to the conference call.

The company will also host a virtual investor event on Wednesday, October 30, 2024, from 4:00 – 5:00 p.m. ET following Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation (CRF). Joe Fitzgerald, executive vice president and president of Cardiology, Dr. Ken Stein, executive vice president and global chief medical officer, Lance Bates, executive vice president and president Interventional Cardiology Therapies (ICTx) and Dr. Janar Sathananthan, chief medical officer ICTx, will present a business update and answer questions from investors.

A live webcast and replay for each event will be accessible at htts://investors.bostonscientific.com. The replays will be available approximately one hour following the completion of each event.

About Boston Scientific
Boston Scientific transforms lives through innovative medical technologies that improve the health of patients around the world. As a global medical technology leader for more than 45 years, we advance science for life by providing a broad range of high-performance solutions that address unmet patient needs and reduce the cost of health care. Our portfolio of devices and therapies helps physicians diagnose and treat complex cardiovascular, respiratory, digestive, oncological, neurological and urological diseases and conditions. Learn more at www.bostonscientific.com and connect on LinkedIn and X, formerly Twitter.  

CONTACTS:
Chanel Hastings
Media Relations
+1 (508) 382-0288
Chanel.Hastings@bsci.com

Anzeige

Aktie im Fokus

Kurse

84,02 $
0,00%
Boston Scientific Chart

Jon Monson
Investor Relations
+1 (508) 683-5450
BSXInvestorRelations@bsci.com

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/boston-scientific-announces-conference-call-discussing-third-quarter-2024-results-302265174.html

SOURCE Boston Scientific Corporation

Werbung

Mehr Nachrichten zur Boston Scientific Aktie kostenlos abonnieren

E-Mail-Adresse
Benachrichtigungen von ARIVA.DE
(Mit der Bestellung akzeptierst du die Datenschutzhinweise)

Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.


Andere Nutzer interessierten sich auch für folgende News